BioPortfolio Blog about Biotechnology, Pharmaceutical and Healthcare

03:57 EDT 26th April 2017 | BioPortfolio

Updates and info from the contributors bringing you

Showing News Articles 1–5 of 13,000+

Wednesday 26th April 2017

Merck KGaA MRK Pharmaceuticals Healthcare Deals and Alliances Profile [Updated: 20032017] Prices from USD $250

SummaryMerck KGaA Merck is a pharmaceutical and chemical company, which operates its business in three markets namely, healthcare market, performance materials market and life sciences market. Its business operations include promoting prescription drugs of chemical and biological origin and overthecounter products for preventive health care and the selftreatment of minor ailments healthcare market...

Tuesday 25th April 2017

Cardiac Dimensions Inc Medical Equipment Deals and Alliances Profile [Updated: 14022017] Prices from USD $250

SummaryCardiac Dimensions Inc Cardiac Dimensions is a medical device company that develops interventional tool used for treating heart failure and other related condition of mitral valve regurgitation. The company's system uses a catheter based approach in order to reshape the mitral valve and thereby reducing mitral regurgitation. Its product includes carillon mitral contour system that is a nons...

Kadimastem Ltd KDST Pharmaceuticals Healthcare Deals and Alliances Profile [Updated: 20032017] Prices from USD $250

SummaryKadimastem Ltd Kadimastem is a biotechnology company that develops and commercializes stem cellbased therapeutics for diabetes and neurodegenerative disorders. The company offers human pluripotent stem cell technology, based on differentiation of human embryonic stem cells towards insulin producing beta cells, and glucagon producing alpha cells arranged in isletlike clusters. Its technology...

The Return Of Medtech Scale-Building?

The largest medtech deal for a year and the fourth-largest ever will see Becton Dickinson become the fifth-placed medical device maker by sales in 2022, EvaluateMedTech data show. At $24bn, its acquisition of C.R. Bard is worth more than half of BD's market cap, and coming just two years after the $12.3bn purchase of Carefusion the deal clearly signals BD's scale-building ambitions.

U.S. Supreme Court may limit where companies can be sued

U.S. Supreme Court justices on Tuesday signaled a willingness to place limits on where corporations can be sued in a dispute involving drug maker Bristol-Myers Squibb Co, a potential setback to plaintiffs' lawyers who try to bring suits in friendly courts. The justices heard arguments in Bristol-Myers' appeal of a California Supreme Court ruling allowing that state's courts to hear cla...

Quick Search